Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FZ-AD005 in advanced solid tumors
NCT06424665Phase 1Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FZ-AD005 in solid tumor (advanced stage), small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
FZ-AD005
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT06424665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424665.